What happens when ChondroFiller gels inside a joint

The key question most patients ask is straightforward: if ChondroFiller® is injected as a liquid, how does it become a stable structure inside the joint? The answer lies in a two-part chemistry that activates only at the moment of delivery.

ChondroFiller® liquid is an ultrapure, native Type I collagen solution. In storage, it is kept under mildly acidic conditions, which hold the collagen molecules in a fluid, injectable state. The product is supplied in a ready-to-use two-chamber syringe — one chamber containing the collagen solution, the other a neutralising buffer. The two components remain physically separated right up to the point of treatment.

When the clinician depresses the plunger during the ultrasound-guided outpatient procedure, a mixing adapter at the syringe tip combines both chambers in a single flow. This raises the pH from acidic storage conditions toward physiological neutral — and that pH shift is the molecular trigger. Native collagen fibres spontaneously assemble into a three-dimensional network without any external heat, catalyst, or chemical crosslinker.

Within 3–5 minutes, the collagen has set into a stable hydrogel scaffold that conforms precisely to the contours of the cartilage defect before solidifying. The process is closer in concept to a two-part adhesive than to anything surgical — a material that stays workable until mixed, then locks into shape exactly where it is needed.

What the set scaffold does inside the defect

Once set, the hydrogel immediately performs two jobs at once — structural and biological — and it begins both from the moment gelation is complete.

On the structural side, the porous three-dimensional matrix fills the defect volume completely, conforming tightly to the edges so that no void remains beneath the joint surface. This matters because an unfilled defect leaves subchondral bone — the dense layer of bone directly beneath cartilage — exposed to the repeated mechanical friction of joint loading. The collagen scaffold interposes itself between bone and the opposing joint surface, acting as a physical buffer while the body's own repair process gets under way.

Equally important is what the scaffold does not contain. ChondroFiller® is entirely acellular: there are no donor cells, no laboratory-cultured tissue, and no genetic material in the implant. Patients sometimes assume that a regenerative injection must deliver the repair cells directly. In this case, the collagen matrix is the environment, not the source — it is the patient's own biology that supplies the cells.

That environment is precisely what makes the scaffold biologically active. The porous collagen network presents a surface chemistry and a physical architecture that emit chemotactic cues, creating the conditions the body needs to begin sending its own progenitor cells into the defect. Protection and recruitment happen simultaneously; the scaffold does not wait to start one role before beginning the other.

How the scaffold calls repair cells into place

Clinicians call this phase acellular matrix-induced chondrogenesis — a term worth unpacking. "Acellular" signals that the implant itself carries no cells; "matrix-induced" is where the mechanism becomes distinctive. Rather than passively occupying a void, the collagen structure actively broadcasts chemotactic cues to the surrounding tissue, prompting the body to supply its own cellular repair workforce without any stem cell injection, marrow harvest, or laboratory preparation step.

Two local cell populations respond to those signals. Mesenchymal stem cells (MSCs) and chondrogenic progenitor cells mobilise from two reservoirs that sit within millimetres of a typical focal cartilage lesion: the subchondral bone marrow immediately beneath the defect floor, and the synovial lining that coats the joint cavity. Because both sources are local, the body can deploy its repair cells quickly once the scaffold is in place.

Crucially, the porous three-dimensional architecture of the collagen matrix is built for full-depth infiltration — not surface colonisation. Recruited cells migrate through the scaffold's open channels into its interior, distributing throughout the defect volume rather than forming a thin cap at the surface. It is this depth of penetration that marks the difference between a biological scaffold and a simple filler: the repair biology takes hold from the inside out, giving the nascent tissue a structural foundation anchored to both the defect walls and the bone beneath.

The molecular pathway from recruited cell to cartilage tissue

Once inside the scaffold, recruited mesenchymal stem cells encounter the collagen matrix at a molecular level — and that encounter is where cartilage reprogramming begins.

The mechanism works like a lock and key. Type I collagen fibres present a surface recognised by integrin-β1 (ITGB1) receptors sitting on the outer membrane of infiltrating stem cells. When integrin-β1 binds to the collagen — the lock engaging — it switches on an internal signalling cascade involving proteins called TGF-β and SMAD2/3. This cascade, documented in peer-reviewed research published in Regenerative Biomaterials (2024), relays the instruction to become cartilage deep into the cell's nucleus, activating SOX9: the master transcription factor that commits a stem cell to a chondrocyte identity.

SOX9, once active, drives production of the two defining building blocks of cartilage tissue — COL2A1 (type II collagen, which gives cartilage its tensile strength) and ACAN (aggrecan, the molecule that allows cartilage to absorb compressive load). These are the hallmark genes of a committed chondrocyte, the cell type the body needs to rebuild a functional joint surface.

The physical character of the gel plays a supporting role here. Research published in Science Advances (2023) found that collagen matrices with faster stress-relaxation — meaning the gel yields slightly under load rather than resisting it rigidly — promote sustained stem-cell survival and more effective chondrogenesis via a ROCK-dependent cytoskeletal pathway. Crosslinked or stiffer gels, by comparison, may impair that process. ChondroFiller's native, uncrosslinked collagen formulation aligns with the faster-relaxing profile this evidence favours.

Early laboratory evidence also points to a possible role for the scaffold in suppressing MMP-13 — the enzyme most responsible for breaking down newly forming repair tissue. Independent clinical confirmation of this effect is not yet available; for now it remains a hypothesis rather than an established property of the scaffold.

What the clinical evidence shows about repair outcomes

Reported outcomes across knee and hip cohorts give a consistent picture for patients with suitable focal defects.

For knee cartilage lesions, data compiled across multiple studies in the manufacturer's Clinical Evaluation Report (version 09, April 2025) show patient-reported International Knee Documentation Committee (IKDC) scores improving by approximately 30 points over 12 months — a clinically meaningful shift on a 100-point scale. MRI-based assessments using the MOCART scoring system, which grades the quality of cartilage repair tissue, range from 70 to 87 in reported series.

Hip evidence comes from a prospective cohort by Mazek and colleagues (2021, PMC), which followed 26 patients with acetabular cartilage lesions larger than 2 cm². At three to five years, 17 of 21 evaluable patients achieved good or excellent results confirmed by MRI — with two patients ultimately requiring total hip replacement. That 3–5 year follow-up window is notable: it suggests the repair tissue, once established, holds up over the medium term in appropriately selected patients.

Two caveats deserve equal billing. First, patients with pre-existing osteoarthritis graded Tönnis 2–3 fared poorly in the hip cohort. The scaffold depends on the body's own repair biology; in a joint where that biology is already substantially compromised by advanced degeneration, the conditions for successful chondrogenesis are less favourable. Patient selection — guided by imaging and clinical assessment — determines a great deal of the outcome.

Second, no independent, randomised controlled trial data have yet been published. The available evidence base is drawn from manufacturer-sponsored evaluations and small observational cohorts. That does not invalidate the findings, but it does mean the evidence should be interpreted with appropriate caution until larger, independent studies are available.

Which patients this pathway is designed for

Suitable candidates share a specific profile: a focal cartilage defect — a defined area of cartilage loss on the joint surface, rather than wear distributed across the whole joint. Clinical evidence covers knee and hip presentations; the Mazek cohort (2021) included acetabular lesions larger than 2 cm², giving a data-supported reference point for defect sizing in the hip. As the outcome data already discussed make clear, advanced osteoarthritis sits outside the indicated range — the section on clinical evidence sets out why.

At MSK Doctors, the pathway begins with a consultant-led assessment that includes an imaging review — MRI where the clinical picture warrants it — to confirm defect morphology, grade background joint health, and determine whether the patient's repair biology is likely to support chondrogenesis. Assessments are available at the Sleaford Regeneration Hub and at the Grantham centre; London-based patients can be seen through the London Cartilage Clinic, the group's Harley Street practice.

Where suitability is confirmed, the collagen scaffold is delivered as an ultrasound-guided outpatient injection — no hospital admission, no general anaesthetic, no surgical wound recovery. For patients with focal defects in otherwise well-preserved joints, this positions ChondroFiller at a meaningful point on the care pathway: beyond conservative management, but considerably less invasive than the surgical options it may help defer.

For patients who meet these criteria, appointments can be booked directly at mskdoctors.com without a GP referral.

1. [1] Role of integrin β1 and tenascin C mediate TGF-SMAD2/3 signaling in chondrogenic differentiation of BMSCs induced by type I collagen hydrogel. (2024). https://doi.org/10.1093/rb/rbae017 https://doi.org/10.1093/rb/rbae017
2. [2] Collagen hydrogel viscoelasticity regulates MSC chondrogenesis in a ROCK-dependent manner. (2023). https://doi.org/10.1126/sciadv.ade9497 https://doi.org/10.1126/sciadv.ade9497